Nektar Therapeutics annual gross margin
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Nektar Therapeutics Gross Margin Growth & History (NKTR)
Nektar Therapeutics's gross margin was 100.00% for fiscal 2025.
View full Nektar Therapeutics company overviewNektar Therapeutics annual gross margin history
| Fiscal year | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | 100.00% | +31.18 pp |
| 2024 | 2024-12-31 | 68.82% | +6.29 pp |
| 2023 | 2023-12-31 | 62.53% | −13.97 pp |
| 2022 | 2022-12-31 | 76.50% | +0.93 pp |
| 2021 | 2021-12-31 | 75.57% | −11.69 pp |
| 2020 | 2020-12-31 | 87.26% | +5.91 pp |
| 2019 | 2019-12-31 | 81.35% | −16.60 pp |
| 2018 | 2018-12-31 | 97.95% | +7.88 pp |
| 2017 | 2017-12-31 | 90.07% | +8.34 pp |
| 2016 | 2016-12-31 | 81.74% | −3.49 pp |
| 2015 | 2015-12-31 | 85.22% | −0.56 pp |
| 2014 | 2014-12-31 | 85.78% | +11.64 pp |
| 2013 | 2013-12-31 | 74.14% | +11.62 pp |
| 2012 | 2012-12-31 | 62.52% | −6.85 pp |
| 2011 | 2011-12-31 | 69.37% | −14.49 pp |
| 2010 | 2010-12-31 | 83.86% | +26.89 pp |
| 2009 | 2009-12-31 | 56.98% | — |
Nektar Therapeutics quarterly gross margin
Q1.10
Q2.10
Q3.10
Q4.10
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
| Fiscal quarter | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| Q4 2025 | 2025-12-31 | 100.00% | +27.34 pp |
| Q3 2025 | 2025-09-30 | 100.00% | +18.38 pp |
| Q2 2025 | 2025-06-30 | 100.00% | +41.47 pp |
| Q1 2025 | 2025-03-31 | 100.00% | +39.44 pp |
| Q4 2024 | 2024-12-31 | 72.66% | +3.15 pp |
| Q3 2024 | 2024-09-30 | 81.62% | +33.10 pp |
| Q2 2024 | 2024-06-30 | 58.53% | −7.35 pp |
| Q1 2024 | 2024-03-31 | 60.56% | −6.74 pp |
| Q4 2023 | 2023-12-31 | 69.51% | −2.19 pp |
| Q3 2023 | 2023-09-30 | 48.51% | −30.44 pp |
| Q2 2023 | 2023-06-30 | 65.88% | −10.42 pp |
| Q1 2023 | 2023-03-31 | 67.31% | −11.28 pp |
| Q4 2022 | 2022-12-31 | 71.70% | −3.66 pp |
| Q3 2022 | 2022-09-30 | 78.95% | +0.27 pp |
| Q2 2022 | 2022-06-30 | 76.30% | +3.37 pp |
| Q1 2022 | 2022-03-31 | 78.59% | +2.93 pp |
| Q4 2021 | 2021-12-31 | 75.36% | −6.22 pp |
| Q3 2021 | 2021-09-30 | 78.69% | −2.77 pp |
| Q2 2021 | 2021-06-30 | 72.94% | −15.24 pp |
| Q1 2021 | 2021-03-31 | 75.66% | −16.81 pp |
| Q4 2020 | 2020-12-31 | 81.57% | −0.74 pp |
| Q3 2020 | 2020-09-30 | 81.45% | −1.68 pp |
| Q2 2020 | 2020-06-30 | 88.18% | +9.70 pp |
| Q1 2020 | 2020-03-31 | 92.46% | +11.74 pp |
| Q4 2019 | 2019-12-31 | 82.31% | +1.05 pp |
| Q3 2019 | 2019-09-30 | 83.14% | +0.37 pp |
| Q2 2019 | 2019-06-30 | 78.48% | −21.01 pp |
| Q1 2019 | 2019-03-31 | 80.72% | −1.79 pp |
| Q4 2018 | 2018-12-31 | 81.27% | −8.52 pp |
| Q3 2018 | 2018-09-30 | 82.77% | −13.52 pp |
| Q2 2018 | 2018-06-30 | 99.49% | +25.48 pp |
| Q1 2018 | 2018-03-31 | 82.52% | +7.31 pp |
| Q4 2017 | 2017-12-31 | 89.78% | +7.42 pp |
| Q3 2017 | 2017-09-30 | 96.29% | +15.65 pp |
| Q2 2017 | 2017-06-30 | 74.01% | −2.47 pp |
| Q1 2017 | 2017-03-31 | 75.21% | −9.73 pp |
| Q4 2016 | 2016-12-31 | 82.37% | +3.61 pp |
| Q3 2016 | 2016-09-30 | 80.64% | −8.08 pp |
| Q2 2016 | 2016-06-30 | 76.48% | +22.96 pp |
| Q1 2016 | 2016-03-31 | 84.94% | −7.30 pp |
| Q4 2015 | 2015-12-31 | 78.76% | +10.97 pp |
| Q3 2015 | 2015-09-30 | 88.72% | −4.34 pp |
| Q2 2015 | 2015-06-30 | 53.51% | −28.57 pp |
| Q1 2015 | 2015-03-31 | 92.24% | +32.23 pp |
| Q4 2014 | 2014-12-31 | 67.79% | −3.45 pp |
| Q3 2014 | 2014-09-30 | 93.06% | +14.20 pp |
| Q2 2014 | 2014-06-30 | 82.09% | −3.12 pp |
| Q1 2014 | 2014-03-31 | 60.01% | +10.70 pp |
| Q4 2013 | 2013-12-31 | 71.23% | +5.71 pp |
| Q3 2013 | 2013-09-30 | 78.86% | +18.12 pp |
| Q2 2013 | 2013-06-30 | 85.20% | +15.61 pp |
| Q1 2013 | 2013-03-31 | 49.31% | −2.18 pp |
| Q4 2012 | 2012-12-31 | 65.53% | +61.58 pp |
| Q3 2012 | 2012-09-30 | 60.74% | +50.99 pp |
| Q2 2012 | 2012-06-30 | 69.59% | +66.70 pp |
| Q1 2012 | 2012-03-31 | 51.49% | +58.47 pp |
| Q4 2011 | 2011-12-31 | 3.95% | +2.93 pp |
| Q3 2011 | 2011-09-30 | 9.75% | +11.75 pp |
| Q2 2011 | 2011-06-30 | 2.89% | −7.70 pp |
| Q1 2011 | 2011-03-31 | −6.98% | +0.44 pp |
| Q4 2010 | 2010-12-31 | 1.02% | — |
| Q3 2010 | 2010-09-30 | −2.00% | — |
| Q2 2010 | 2010-06-30 | 10.59% | — |
| Q1 2010 | 2010-03-31 | −7.43% | — |
Nektar Therapeutics gross margin trends
Over the last five fiscal years, Nektar Therapeutics's gross margin increased from 87.26% to 100.00%, a change of +12.74 percentage points. The latest reported quarter, Q4 2025, shows 100.00%.
About the metric
What gross margin means
Gross margin measures the percentage of revenue remaining after the direct costs of producing goods or services. It helps show how efficiently a company turns sales into gross profit before operating expenses.
Calculation and source
How gross margin is calculated
TickerStat calculates gross margin as SEC-reported gross profit divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Nektar Therapeutics source filings ↗